Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives
Acute respiratory distress syndrome (ARDS) represents a current challenge for medicine due to its incidence, morbidity and mortality and, also, the absence of an optimal treatment. The COVID-19 outbreak only increased the urgent demand for an affordable, safe and effective treatment for this process...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/15/7850 |
| _version_ | 1797525569505591296 |
|---|---|
| author | Silvia Fernández-Francos Noemi Eiro Natalia González-Galiano Francisco J. Vizoso |
| author_facet | Silvia Fernández-Francos Noemi Eiro Natalia González-Galiano Francisco J. Vizoso |
| author_sort | Silvia Fernández-Francos |
| collection | DOAJ |
| description | Acute respiratory distress syndrome (ARDS) represents a current challenge for medicine due to its incidence, morbidity and mortality and, also, the absence of an optimal treatment. The COVID-19 outbreak only increased the urgent demand for an affordable, safe and effective treatment for this process. Early clinical trials suggest the therapeutic usefulness of mesenchymal stem cells (MSCs) in acute lung injury (ALI) and ARDS. MSC-based therapies show antimicrobial, anti-inflammatory, regenerative, angiogenic, antifibrotic, anti-oxidative stress and anti-apoptotic actions, which can thwart the physiopathological mechanisms engaged in ARDS. In addition, MSC secretome and their derived products, especially exosomes, may reproduce the therapeutic effects of MSC in lung injury. This last strategy of treatment could avoid several safety issues potentially associated with the transplantation of living and proliferative cell populations and may be formulated in different forms. However, the following diverse limitations must be addressed: (i) selection of the optimal MSC, bearing in mind both the heterogeneity among donors and across different histological origins, (ii) massive obtention of these biological products through genetic manipulations of the most appropriate MSC, (iii) bioreactors that allow their growth in 3D, (iv) ideal culture conditions and (v) adequate functional testing of these obtaining biological products before their clinical application. |
| first_indexed | 2024-03-10T09:14:47Z |
| format | Article |
| id | doaj.art-35f1498df6944052b850ea8e68dbf67d |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:14:47Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-35f1498df6944052b850ea8e68dbf67d2023-11-22T05:39:23ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012215785010.3390/ijms22157850Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future PerspectivesSilvia Fernández-Francos0Noemi Eiro1Natalia González-Galiano2Francisco J. Vizoso3Research Unit, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, SpainResearch Unit, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, SpainDepartment of Internal Medicine, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, SpainResearch Unit, Fundación Hospital de Jove, Av. Eduardo Castro, 161, 33290 Gijón, SpainAcute respiratory distress syndrome (ARDS) represents a current challenge for medicine due to its incidence, morbidity and mortality and, also, the absence of an optimal treatment. The COVID-19 outbreak only increased the urgent demand for an affordable, safe and effective treatment for this process. Early clinical trials suggest the therapeutic usefulness of mesenchymal stem cells (MSCs) in acute lung injury (ALI) and ARDS. MSC-based therapies show antimicrobial, anti-inflammatory, regenerative, angiogenic, antifibrotic, anti-oxidative stress and anti-apoptotic actions, which can thwart the physiopathological mechanisms engaged in ARDS. In addition, MSC secretome and their derived products, especially exosomes, may reproduce the therapeutic effects of MSC in lung injury. This last strategy of treatment could avoid several safety issues potentially associated with the transplantation of living and proliferative cell populations and may be formulated in different forms. However, the following diverse limitations must be addressed: (i) selection of the optimal MSC, bearing in mind both the heterogeneity among donors and across different histological origins, (ii) massive obtention of these biological products through genetic manipulations of the most appropriate MSC, (iii) bioreactors that allow their growth in 3D, (iv) ideal culture conditions and (v) adequate functional testing of these obtaining biological products before their clinical application.https://www.mdpi.com/1422-0067/22/15/7850COVID-19pneumoniaacute respiratory distress syndromeacute lung injurymesenchymal stem cellsexosomes |
| spellingShingle | Silvia Fernández-Francos Noemi Eiro Natalia González-Galiano Francisco J. Vizoso Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives International Journal of Molecular Sciences COVID-19 pneumonia acute respiratory distress syndrome acute lung injury mesenchymal stem cells exosomes |
| title | Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives |
| title_full | Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives |
| title_fullStr | Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives |
| title_full_unstemmed | Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives |
| title_short | Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives |
| title_sort | mesenchymal stem cell based therapy as an alternative to the treatment of acute respiratory distress syndrome current evidence and future perspectives |
| topic | COVID-19 pneumonia acute respiratory distress syndrome acute lung injury mesenchymal stem cells exosomes |
| url | https://www.mdpi.com/1422-0067/22/15/7850 |
| work_keys_str_mv | AT silviafernandezfrancos mesenchymalstemcellbasedtherapyasanalternativetothetreatmentofacuterespiratorydistresssyndromecurrentevidenceandfutureperspectives AT noemieiro mesenchymalstemcellbasedtherapyasanalternativetothetreatmentofacuterespiratorydistresssyndromecurrentevidenceandfutureperspectives AT nataliagonzalezgaliano mesenchymalstemcellbasedtherapyasanalternativetothetreatmentofacuterespiratorydistresssyndromecurrentevidenceandfutureperspectives AT franciscojvizoso mesenchymalstemcellbasedtherapyasanalternativetothetreatmentofacuterespiratorydistresssyndromecurrentevidenceandfutureperspectives |